MA55590A - Gène 1 induit par l'interleukine 4 (il4i1) en tant que biomarqueur et ses utilisations - Google Patents
Gène 1 induit par l'interleukine 4 (il4i1) en tant que biomarqueur et ses utilisationsInfo
- Publication number
- MA55590A MA55590A MA055590A MA55590A MA55590A MA 55590 A MA55590 A MA 55590A MA 055590 A MA055590 A MA 055590A MA 55590 A MA55590 A MA 55590A MA 55590 A MA55590 A MA 55590A
- Authority
- MA
- Morocco
- Prior art keywords
- il4i1
- biomarker
- interleukin
- gene
- induced
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19168304.4A EP3721894A1 (de) | 2019-04-10 | 2019-04-10 | Interleukin-4-induziertes gen 1 (il4i1) als biomarker und verwendungen davon |
Publications (1)
Publication Number | Publication Date |
---|---|
MA55590A true MA55590A (fr) | 2022-02-16 |
Family
ID=66105002
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA055590A MA55590A (fr) | 2019-04-10 | 2020-04-09 | Gène 1 induit par l'interleukine 4 (il4i1) en tant que biomarqueur et ses utilisations |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220170096A1 (de) |
EP (2) | EP3721894A1 (de) |
JP (1) | JP2022529423A (de) |
KR (1) | KR20210151182A (de) |
CN (1) | CN114126634A (de) |
AU (1) | AU2020271634A1 (de) |
CA (1) | CA3136524A1 (de) |
IL (1) | IL286928A (de) |
MA (1) | MA55590A (de) |
WO (1) | WO2020208190A1 (de) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10894812B1 (en) | 2020-09-30 | 2021-01-19 | Alpine Roads, Inc. | Recombinant milk proteins |
AU2021353004A1 (en) | 2020-09-30 | 2023-04-13 | Nobell Foods, Inc. | Recombinant milk proteins and food compositions comprising the same |
US10947552B1 (en) | 2020-09-30 | 2021-03-16 | Alpine Roads, Inc. | Recombinant fusion proteins for producing milk proteins in plants |
KR102465358B1 (ko) | 2021-11-05 | 2022-11-11 | 주식회사 엑티브온 | 마그놀올, 호노키올, 또는 이의 조합을 포함하는 피부 외용제용 보존제 및 이를 포함하는 화장료 조성물 |
CN115044567B (zh) * | 2022-04-07 | 2023-12-12 | 北京大学 | 一种肺癌的代谢免疫靶点il4i1及其应用 |
CN115785277B (zh) * | 2022-09-09 | 2023-06-20 | 上海百英生物科技股份有限公司 | 一种抗IL4i1纳米抗体的制备及其应用 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010066858A1 (en) * | 2008-12-10 | 2010-06-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment and the prognosis of cancer |
US9175266B2 (en) | 2012-07-23 | 2015-11-03 | Gamida Cell Ltd. | Enhancement of natural killer (NK) cell proliferation and activity |
US11427600B2 (en) | 2014-06-27 | 2022-08-30 | Nogra Pharma Limited | Aryl receptor modulators and methods of making and using the same |
EP3191186B1 (de) | 2014-09-10 | 2021-01-27 | Georgetown University | Zusammensetzungen und verfahren zur verwendung von interleukin-4-induziertem gen 1 (il4i1) |
WO2017083809A1 (en) | 2015-11-13 | 2017-05-18 | The Brigham And Women's Hospital, Inc. | Targeting oxazole structures for therapy against inflammatory diseases |
WO2017189353A1 (en) * | 2016-04-26 | 2017-11-02 | Five Prime Therapeutics, Inc. | Treating respiratory diseases by targeting interleukin 4 induced 1 (il4i1) |
CR20180556A (es) | 2016-05-25 | 2019-04-23 | Deutsches Krebsforschungszentrum Dkfz | 3-oxo-2, 6-difenil-2,3-dihidropiridazin-4-carboxamidas |
UY37466A (es) | 2016-11-03 | 2018-01-31 | Phenex Discovery Verwaltungs Gmbh | N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa |
JOP20190193A1 (ar) | 2017-02-09 | 2019-08-08 | Bayer Pharma AG | ممركبات 2-أريل غير متجانس-3-أكسو-2، 3-ثنائي هيدرو بيريدازين-4-كربوكساميد لمعالجة السرطان |
WO2019101641A1 (en) | 2017-11-21 | 2019-05-31 | Bayer Aktiengesellschaft | 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor anatgonists |
WO2019101647A1 (en) | 2017-11-21 | 2019-05-31 | Bayer Aktiengesellschaft | 2-phenylpyrimidine-4-carboxamides as ahr inhibitors |
WO2019101642A1 (en) | 2017-11-21 | 2019-05-31 | Bayer Aktiengesellschaft | Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides |
WO2019101643A1 (en) | 2017-11-21 | 2019-05-31 | Bayer Aktiengesellschaft | 3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides |
WO2019115586A1 (en) | 2017-12-12 | 2019-06-20 | Phenex Discovery Verwaltungs-GmbH | Oxalamides as modulators of indoleamine 2,3-dioxygenase |
US20210122757A1 (en) | 2018-03-29 | 2021-04-29 | Phenex Discovery Verwaltungs-GmbH | Spirocyclic compounds as modulators of indoleamine 2,3-dioxygenase |
WO2019206800A1 (en) | 2018-04-24 | 2019-10-31 | Phenex Discovery Verwaltungs-GmbH | Spirocyclic compounds as modulators of indoleamine 2,3-dioxygenase |
WO2020021024A1 (en) | 2018-07-26 | 2020-01-30 | Phenex Pharmaceuticals Ag | Substituted bicyclic compounds as modulators of the aryl hydrocarbon receptor (ahr) |
AU2019323714A1 (en) | 2018-08-24 | 2021-03-25 | Jaguahr Therapeutics Pte Ltd | Tetrahydropyridopyrimidine derivatives as AhR modulators |
SG11202101499UA (en) | 2018-08-31 | 2021-03-30 | Jaguahr Therapeutics Pte Ltd | Heterocyclic compounds as ahr modulators |
-
2019
- 2019-04-10 EP EP19168304.4A patent/EP3721894A1/de not_active Withdrawn
-
2020
- 2020-04-09 CA CA3136524A patent/CA3136524A1/en active Pending
- 2020-04-09 KR KR1020217036784A patent/KR20210151182A/ko unknown
- 2020-04-09 WO PCT/EP2020/060259 patent/WO2020208190A1/en unknown
- 2020-04-09 MA MA055590A patent/MA55590A/fr unknown
- 2020-04-09 JP JP2021560638A patent/JP2022529423A/ja active Pending
- 2020-04-09 CN CN202080027697.5A patent/CN114126634A/zh active Pending
- 2020-04-09 US US17/602,361 patent/US20220170096A1/en active Pending
- 2020-04-09 EP EP20716827.9A patent/EP3952901A1/de active Pending
- 2020-04-09 AU AU2020271634A patent/AU2020271634A1/en active Pending
-
2021
- 2021-10-03 IL IL286928A patent/IL286928A/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2020208190A1 (en) | 2020-10-15 |
CA3136524A1 (en) | 2020-10-15 |
US20220170096A1 (en) | 2022-06-02 |
AU2020271634A1 (en) | 2021-12-02 |
EP3721894A1 (de) | 2020-10-14 |
EP3952901A1 (de) | 2022-02-16 |
KR20210151182A (ko) | 2021-12-13 |
CN114126634A (zh) | 2022-03-01 |
IL286928A (en) | 2021-10-31 |
JP2022529423A (ja) | 2022-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA55590A (fr) | Gène 1 induit par l'interleukine 4 (il4i1) en tant que biomarqueur et ses utilisations | |
BR112018001955A2 (pt) | anticorpos monoclonais contra bcma | |
MA50638A (fr) | Biomarqueurs associés aux maladies médiées par l'interleukine-33 (il-33) et leurs utilisations | |
BR112018074468A2 (pt) | anticorpos anti-cd40 e suas utilizações | |
AR086470A1 (es) | Metodo implementado por un dispositivo de computacion y aparatos que utilizan tecnicas de canales de color y marcadores opticos | |
MA55080A (fr) | Anticorps anti-mertk à affinité élevée et utilisations associées | |
BR112018014355A2 (pt) | processos para a preparação de f-benzoxazinorifamicina i e para a preparação de 2-amino-5-fluorobenzeno-1,3-diol iii | |
BR112021014944A2 (pt) | Toxinas apxia, apxiia e apxiiia inativas | |
MA52190A (fr) | Anticorps anti-trem-1 et utilisations associées | |
CO2022001021A2 (es) | Anticuerpos que se unen a células cancerosas yque dirigen radionucleidos a dichas células | |
BR112017005430A2 (pt) | um polímero orgânico curável que compreende pelo menos uma unidade de acilureia, sua preparação e uso. | |
WO2018203864A3 (en) | ECOLOGICAL PRIMARY EXPLOSIVE | |
BR112021026508A2 (pt) | Sílica precipitada e processo para sua fabricação | |
EA202190228A1 (ru) | Модификация связывающих молекул для минимизации уже существующих взаимодействий | |
AU2018203040A1 (en) | Combined fixing tool | |
EA202190229A1 (ru) | Безопасная для сердца антидиабетическая терапия | |
TR201901321U5 (tr) | eğitim seti | |
UA39904S (uk) | Рекламний аркуш | |
TH167282A (th) | แผ่นชีทเหล็กกล้าสำหรับกระป๋อง และวิธีการทำการผลิตของพวกมัน | |
JP1715569S (ja) | 用箋挟 | |
JP1715568S (ja) | 用箋挟 | |
TR201903631A2 (tr) | Sağlikli bi̇reylerde ve poli̇ki̇sti̇k over sendromunda (pkos) yeni̇ over rezervi̇ beli̇rteci̇ olarak mi̇dki̇n protei̇ni̇ | |
UA44608S (uk) | Ваги торгівельні | |
UA40882S (uk) | Вивіска | |
UA40739S (uk) | Вивіска |